Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

 

  • Neurotransmitter based
  • Neuroprotective
  • Anti-inflammatory
  • Cognitive enhancers

Related Conference of Drug Development in Dementia

February 25-26, 2019

4th International Conference on Clinical and Counseling Psychology

| Radisson Hotel Narita | Tokyo, Japan
February 27-28, 2019

7th World Congress on Depression and Anxiety

Courtyard Marriott Seoul Times Square, Seoul, South Korea

March 14 & 15, 2019

European Autism Congress

| Zagreb, Croatia
March, 14-15, 2019 |

European Psychiatrists Meeting

Zagreb, Croatia.
March 18-19, 2019

31st American Psychiatry, Psychology and Nursing Congress

Chicago, Illinois, USA
June 10-11, 2019

10th International Conference on Addiction & Psychiatry

Helsinki, Finland
June 13th - 15th 2019

2nd Annual Congress on Mental Health

Amsterdam, Netherlands
June 24-25, 2019

31stWorld Psychiatrists and Psychologists Meet

Ho Chi Minh City, Vietnam
July 22-23, 2019

2nd Annual Congress on Psychiatric & Mental Health Nursing

Amsterdam, Netherlands
August 14-15, 2019

30th International Conference on Psychiatry and Mental Health

Radisson Hotel Narita, Tokyo, Japan

Drug Development in Dementia Conference Speakers

Recommended Sessions

Related Journals

Are you interested in